• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection. A morphologic and molecular genetic study

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2016 Jul 14. doi: 10.1111/irv.12410. [Epub ahead of print]
[h=1]Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection. A morphologic and molecular genetic study.[/h] Voltersvik P[SUP]1[/SUP], Aqrawi LA[SUP]1,[/SUP][SUP]2[/SUP], Dudman S[SUP]3[/SUP], Hungnes O[SUP]3[/SUP]; Norwegian lung pathology group, Bostad L[SUP]4[/SUP], Brokstad KA[SUP]5[/SUP], Cox RJ[SUP]1,[/SUP][SUP]2,[/SUP][SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] During the pandemic outbreak of the 2009 swine influenza (A(H1N1)pdm09) 32 fatal cases occurred in Norway, 19 of these were included in the study.
[h=4]OBJECTIVES:[/h] we characterised pulmonary changes in these fatal Norwegian cases.
[h=4]PATIENTS AND METHODS:[/h] Upon hospitalisation, detailed clinical information and specimens from the upper and lower respiratory pathways were collected. At post-mortem lung tissue was collected, formalin fixed and paraffin embedded. Immunohistochemical and light microscopic examination were performed to visualise the local expression of the A(H1N1)pdm09 virus. Reverse transcription-polymerase chain reaction (RT-PCR) and pyrosequencing of the non-fixed specimens, allowed the identification of mutations in the influenza virus surface glycoprotein (haemagglutinin gene) particularly at position 222.
[h=4]RESULTS AND CONCLUSIONS:[/h] The overall course of illness lasted from 2 to 40 days (median 9 days). Diffused alveolar damage (DAD) was evident in 11 cases, 4 of which had no apparent underlying illness. Obesity was prominent in 12 cases, where 3 individuals were classified as otherwise healthy. The HA D222G mutation was detected in 6 cases, 3 of which had no underlying illness. Immunohistochemistry showed the A(H1N1)pdm09 virus to be prominent at the site of inflammation both in close proximity to and inside alveolar structures in the lung tissue. In addition to a possible role for the HA D222G mutation, our findings indicate that host factors and underlying conditions in the infected individuals are fundamental for disease outcome in many cases. This study increases our understanding of determinants for the clinical outcome of pandemic influenza, which could guide future treatment. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] 2009 pandemic; HA pyrosequencing; Immunohistochemistry; Influenza; Lung

PMID: 27413002 DOI: 10.1111/irv.12410
[PubMed - as supplied by publisher]
 
Back
Top Bottom